Amy Dezern, MD, MHS, describes the currently available first-line treatment options for patients with MDS.
Videos
Dr Chen presents statistics on the incidence of chronic graft versus host disease.
Expert perspectives on the mechanisms of resistance to frontline therapy in HR+/HER2- metastatic breast cancer and results from key clinical trials analyzing the safety and efficacy of rechallenging with prior therapy.
Sagun Shrestha, MD, discusses how the addition of atezolizumab and durvalumab to treatment options for patients with extensive stage small cell lung cancer has impacted the field for the better.
Eric A. Singer, MD, discusses recent research evaluating adjuvant therapies for patients with high-risk renal cell carcinoma.
A key opinion leader on relapsed/refractory chronic lymphocytic leukemia provides practical advice on patient management and looks toward future evolutions in the treatment landscape.
Comprehensive insight to cardiovascular safety data with available therapies and how current understandings may impact the management of patients with relapsed/refractory chronic lymphocytic leukemia.
Centering conversation on patients with relapsed/refractory chronic lymphocytic leukemia, Andrew Lipsky, MD, reviews efficacy data and considers how it impacts treatment selection.
Shared insight on ELEVATE-RR, which utilized acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Expert perspectives on the ALPINE trial of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Andrew Lipsky, MD, considers the role of BTK inhibitors as second-line therapy in patients with relapsed/refractory chronic lymphocytic leukemia.
Joseph M. Scandura, MD, PhD, discusses research regarding pelabresib for patients with myeloproliferative neoplasms.
Michael Wang, MD, discusses the background of the phase 3 BRUIN MCL-321 trial and how positive results may shape the future of the mantle cell lymphoma space.
Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key NSCLC data updates discussed following the 2023 ASCO Annual Meeting.
A review of recently updated data from KEYNOTE-671, focused on perioperative use of pembrolizumab in early-stage non–small cell lung cancer.
Following ASCO 2023, experts in oncology review recent data updates from KEYNOTE-789 on chemotherapy with or without pembrolizumab for TKI-resistant nonsquamous NSCLC.
Charu Aggarwal, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data updates from the ADAURA trial, an overall survival analysis of osimertinib in non–small cell lung cancer (NSCLC).
Jeffrey Dome, MD, PhD, discusses how the use of atezolizumab has impacted the treatment of pediatric patients with alveolar soft part sarcoma.
A discussion on the toxicities associated with mTOR inhibitors and which patients with PEComa would be considered good candidates.
Dr Andrew Wagner shares data from the AMPECT trial investigating the potential role of mTOR inhibitors in PEComa.
Jonathan C. Trent, MD, PhD, discusses the molecular analyses of the INTRIGUE study, which was supported by Caris Life Science’s Precision Oncology Alliance, investigating patients with GIST that were presented at ASCO 2023.
Ruchi Garg, MD, discusses the option of immunotherapy for the treatment of endometrial cancer.
Following their interview with Stephanie Graff, MD, FACP, the Oncology Brothers share key takeaways from the NATALEE, SONIA, and X-7/7 trials and consider how they will impact the management of breast cancer.
The Oncology Brothers, joined by Stephanie Graff, MD, FACP, share their thoughts on data from the X-7/7 trial of fixed-dose capecitabine in patients with metastatic breast cancer.
Shared insight from the Oncology Brothers and Stephanie Graff, MD, FACP, on the role of CDK4/6 inhibition in combination with aromatase inhibitor therapy following data from the SONIA trial in HR+ metastatic breast cancer.
Expert oncologist Stephanie Graff, MD, FACP, joins the Oncology Brothers to review data from the NATALEE trial and consider the role of adjuvant ribociclib in patients with HR+ breast cancer.
Nicholas J. Roberts, discusses real-world research around the adoption of germline testing for breast cancer, and the testing gap in certain racial groups.
Colleen Danielson, NP shares the signs and symptoms she commonly sees in patients with graft versus host disease.
Yi-Bin Chen leads the panel in a review of various GVHD prophylaxis regimens.
David S. Hong, MD, discusses which disease subgroups may benefit from treatment with larotrectinib.